arrow
S

Stefanie Hayoz

swiss cancer institute
H指数:28
被引数:3,456

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

SAKK 35/14随机试验:利妥昔单抗联合或不联合伊布替尼治疗初治滤泡性淋巴瘤患者

2026-09-060
OAAI
Impact of Postoperative Antithrombotic Treatment on Patency and Survival After Open Posterior Popliteal Artery Aneurysm Repair: A Multicenter Retrospective Cohort Analysis from the PARADE Study

术后抗凝治疗对开放性腘动脉瘤修复术后通畅性和生存率的影响:PARADE研究中的一项多中心回顾性队列分析

2026-07-100
OAAI
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16)

TLD-1,一种新型脂质体多柔比星,在实体瘤患者中的比较药代动力学及一项多中心Ⅰ期研究(SAKK 65/16)的最终结果

2025-11-180
PRE
Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

性别特异性的疗效和安全性结局:在接受新辅助治疗的可切除III期非小细胞肺癌(NSCLC)患者中的联合分析——SAKK试验16/96、16/00、16/01、16/08和16/14

2025-11-100
OAAI
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases

一线免疫治疗±化疗,联合或不含 upfront 立体定向放射治疗(SRT)在无症状脑转移的非小细胞肺癌(NSCLC)患者中的应用

2025-11-030
PRE
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2025-09-300
OAAI
Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09/10 dose escalation trial

根治性放疗后长期尿失禁及其影响因素:SAKK 09/10剂量递增试验结果

2025-07-080
PRE
Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57–18, ABCSG-53, GBG 101)

临床淋巴结阳性乳腺癌患者原发肿瘤和淋巴结转移的基因组分析:TAXIS(OPBC-03、SAKK 23/16、IBCSG 57–18、ABCSG-53、GBG 101)框架下的前瞻性队列研究

2025-06-180
PRE
Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment-A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report

接受新辅助治疗后未进行根治性手术的可切除III期NSCLC患者的结局——SAKK试验16/96、16/00、16/01、16/08和16/14的回顾性分析:简报

2025-06-010
OAAI
Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials

预测前列腺癌放疗剂量反应:NRG/RTOG 0126和SAKK 09/10随机III期试验中辐射特征验证

2025-02-010
OAAI
Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography–guided Salvage Radiotherapy Following Prostatectomy

前列腺切除术后的前列腺特异性膜抗原正电子发射断层扫描引导的挽救性放射治疗可带来更好的肿瘤学结局

2024-11-270
OAAI
Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients: The phase III, prospective-randomized placebo-controlled multicenter SAKK 41/13 trial

PIK3CA突变结直肠癌患者的辅助阿司匹林治疗:SAKK 41/13 III期、前瞻性随机安慰剂对照多中心试验

2024-09-013
PRE
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)
2024-04-013
OAAI
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine
2024-03-083
PRE
ASO Visual Abstract: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023-11-130
PRE
Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
2023-10-305
OAAI